Vardenafil reverses erectile dysfunction induced by paroxetine in rats

International Journal of Impotence Research

Volumn 15, Issue 2, 2003, Pages 90-93

  Angulo, J ^a   Bischoff, E ^b   Gabancho, S ^a   Cuevas, P ^a   Saenz de Tejada I ^a,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b BAYER AG   (Germany)

^c NONE   (Spain)

Author keywords

Erectile dysfunction; Nitric oxide; Phosphodiesterase inhibitor; Selective serotonin reuptake inhibitor

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAROXETINE; PHOSPHODIESTERASE INHIBITOR; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAVERNOSAL NERVE ELECTRICAL STIMULATION; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG INHIBITION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; IMPOTENCE; INTRACAVERNOSAL PRESSURE; MALE; NERVE STIMULATION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RAT;

ANIMALS; ELECTRIC STIMULATION; IMIDAZOLES; IMPOTENCE; INJECTIONS, INTRAVENOUS; MALE; PAROXETINE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SULFONES; TRIAZINES;

EID: 0037562888     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900950     Document Type: Article

References (18)

1. Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull 1997; 33: 755-760.
2. Labbate LA et al. Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther 1998; 24: 3-12.
3. Kennedy SH et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61: 276-281.
4. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152: 1514-1516.
5. Nemeroff CB. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 1993; 13(Suppl 2): 10S-17S.
6. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 (Suppl 3): 10-21.
7. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32: 653-658.
8. Ignarro LJ et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843-850.
9. Kim N, Azadzoi KM, Goldstein I, Sáenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88: 112-118.
10. Angulo J et al. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br J Pharmacol 2001; 134: 1190-1194.
11. Sáenz de Tejada I et al. The phosphodiesterase inhibitory selectivity and the in vivo and in vitro potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-290.
12. Sáenz de Tejada I et al. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am J Physiol 1991; 260: H1590-H1595.
13. G-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand 1991; 143: 299-304.
14. Taher A et al. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 1997; 15: 32-35.
15. Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199.
16. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 (Suppl 1): 1-21.
17. Gupta S, Droney T, Masand P, Ashton AK. SSRI-induced sexual dysfunction treated with sildenafil. Depress Anxiety 1999; 9: 180-182.
18. Nurnberg HG et al. Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Serv 1999; 50: 1076-1078.